Merck

Executive Summary

Merck & Co., Inc. is a global biopharmaceutical leader with a diversified portfolio spanning oncology, vaccines, and specialty therapeutics. The company's cornerstone product, Keytruda (pembrolizumab), continues to drive growth through label expansions in earlier-stage and adjuvant settings, while its vaccine franchise (Gardasil, Prevnar) benefits from strong demand and geographic expansion. Merck's late-stage pipeline includes promising assets in immuno-oncology, such as vibostolimab and MK-1084 (KRAS G12C inhibitor), as well as novel cardiovascular and infectious disease programs. With a robust balance sheet and a focus on strategic acquisitions (e.g., Acceleron), Merck is well-positioned to navigate the upcoming Keytruda patent cliff in 2028 through pipeline diversification. The company's commitment to R&D and commercial execution supports sustained long-term value creation. Key near-term catalysts include regulatory actions and clinical data readouts that could further strengthen its therapeutic leadership.

Upcoming Catalysts (preview)

• Q2 2026Keytruda FDA decision for Stage II NSCLC adjuvant therapy90% success
• Q3 2026Gardasil 9 label expansion for adults aged 45-5565% success
• Q4 2026Phase 3 readout for sotatercept in pulmonary arterial hypertension (WIN-OW trial)80% success